Back

The gut-microbiome derived phenylacetylglutamine predicts adverse events in patients with acute coronary syndromes

31 August 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Advancing cardiac care in acute coronary syndromes: from genetics to social determinants Biomarkers ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speakers

Photo
Mrs Meret Sarah Allemann

University of Zurich, Zurich (Switzerland)

Photo
Doctor Carolina Balbi

University of Zurich, Zurich (Switzerland)

8 More presentations in this session

Presentation thumbnail
Symptoms and ASCVD score fail to identify majority of the patients at risk of first myocardial infarction
Doctor A. Mueller (New York, US)
Abstract Slides
Presentation thumbnail
Corrected timi frame count : time to replace the TIMI flow?
Mr S. Rifqi (Semarang, ID)
Abstract Slides
Presentation thumbnail
Expression of cardiomyopathy-related genes in mononuclear blood cells predicts all-cause mortality in patients presenting with acute versus chronic coronary syndrome requiring revascularisation
Doctor A. Teren (Bielefeld, DE)
Abstract Slides Video
Presentation thumbnail
Undiagnosed Diabetes Mellitus is an important risk factor in secondary prevention after an acute coronary syndrome and warrants active screening
Ms E. Woelders (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Influence of social factors on prompt reperfusion in patients with ST-segment elevation myocardial infarction: results from the KRAMI multicenter registry
Doctor Z. Song (Busan, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Advancing cardiac care in acute coronary syndromes: from genetics to social determinants

The Event

Event poster

ESC Congress 2024

31 August 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Gut microbiome-derived metabolites as prognostic biomarkers in heart failure: a systematic review and meta-analysis
thumbnail
Congress Presentation
Alterations of gut microbiome profiles as potential markers in patients developing acute coronary syndrome
thumbnail
Congress Presentation
Gut microbiota-derived imidazole propionate is a novel marker of cardiometabolic risk in patients with coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources